Bank of America’s Eterna Therapeutics ERNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1
Closed -$41 6083
2025
Q4
$41 Hold
1
﹤0.01% 6996
2025
Q3
$36 Hold
1
﹤0.01% 8082
2025
Q2
$39 Hold
1
﹤0.01% 8148
2025
Q1
$55 Hold
1
﹤0.01% 7960
2024
Q4
$87 Buy
+1
New +$271 ﹤0.01% 7765
2024
Q3
Hold
0
7667
2024
Q2
Hold
0
7825
2023
Q2
Hold
0
-$31 7764
2023
Q1
Hold
0
7546
2022
Q4
Hold
0
7909
2022
Q3
Hold
0
7660
2022
Q2
Sell
-6
Closed -$43.1K 7860
2022
Q1
$86K Sell
6
-10
-63% -$190K ﹤0.01% 6934
2021
Q4
$486K Buy
16
+13
+433% +$707K ﹤0.01% 5892
2021
Q3
$202K Buy
3
+2
+200% +$173K ﹤0.01% 6306
2021
Q2
$175K Buy
+1
New +$144K ﹤0.01% 6182
2021
Q1
Hold
0
7511
2020
Q1
Hold
0
6951
2019
Q4
Hold
0
7163
2019
Q3
Hold
0
7313
2019
Q1
Hold
0
-$2K 7181
2018
Q4
Hold
0
6895
2018
Q3
Hold
0
7314
2018
Q2
Hold
0
7142
2018
Q1
Hold
0
7158
2017
Q4
Hold
0
7076
2017
Q3
Hold
0
7105
2016
Q4
Hold
0
7112
2016
Q3
Hold
0
7165
2014
Q1
Hold
0
-$111K 7862
2013
Q4
Hold
0
6051
2013
Q3
Hold
0
6318
2013
Q2
Hold
0
6361

Other funds holding ERNA

Bank of America's ERNA Position: Q1 2026 in Review

Bank of America sold out of Eterna Therapeutics (ERNA) in Q1 2026, closing a stake of 1 share — an estimated $41 sold.

Bank of America first reported a position in ERNA in Q2 2021 and held it in 9 quarters. The position peaked at $486K in Q4 2021. 15 funds tracked by Wall St. Rank hold ERNA as of Q1 2026.

  • Bank of America reported no remaining Eterna Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 1 Eterna Therapeutics share in Q1 2026, an estimated $41.
  • Bank of America first reported a position in Eterna Therapeutics in Q2 2021 and held it in 9 quarters.
  • Bank of America's Eterna Therapeutics position peaked at $486K in Q4 2021.
  • 15 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.